Core Viewpoint - The company announced a provision for asset impairment totaling 147.68 million yuan for the year 2024, significantly impacting its net profit and reflecting a cautious approach to financial reporting [1][2]. Summary by Sections Asset Impairment Provision Overview - The company recognized an inventory impairment provision of 129.23 million yuan, which will reduce the total profit for 2024 by the same amount, leading to a net profit decrease of 118.20 million yuan, accounting for 58.63% of the audited net profit for the year [1][2]. Specifics of the Impairment Provision - The total asset impairment loss amounted to 147.68 million yuan, which includes: - Credit impairment losses for accounts receivable: 12.82 million yuan - Credit impairment losses for other receivables: 3.51 million yuan - Inventory impairment loss: 129.23 million yuan - Contract asset impairment loss: 2.13 million yuan [1][2]. Impact on Financial Statements - The total provision for asset and credit impairment losses will decrease the company's equity by 132.89 million yuan as of the end of the reporting period [2]. Opinions from the Board and Supervisory Committee - The Board's Audit Committee and the Supervisory Committee both approved the asset impairment provision, affirming that it aligns with the principles of prudence and complies with accounting standards, thereby accurately reflecting the company's financial status [3][4][6].
皓元医药: 上海皓元医药股份有限公司关于公司计提资产减值准备的公告